PDGFRB and glioblastoma: Further, one study showed that combination therapy of Imatinib and Nilotinib—a second-generation TKI that also targets PDGFR and c-KIT—did not damage GBM cells as anticipated but rather enhanced their migration and invasion via increased tyrosine phosphorylation of p130Cas, FAK, and the downstream adaptor protein paxillin [274].